Endoscopic Ultrasound

REVIEW ARTICLE
Year
: 2021  |  Volume : 10  |  Issue : 1  |  Page : 19--24

EUS-through-the-needle microbiopsy forceps in pancreatic cystic lesions: A systematic review


Vasile Daniel Balaban1, Irina M Cazacu2, Larisa Pinte3, Mariana Jinga1, Manoop S Bhutani5, Adrian Saftoiu5 
1 Internal Medicine and Gastroenterology Clinic, “Carol Davila” University of Medicine and Pharmacy, Craiova; Department of Gastroenterology, “Dr. Carol Davila” Central Military Emergency University Hospital, Bucharest, Romania
2 Department of Gastroenterology, Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Craiova, Romania; Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
3 Department of Internal Medicine, Colentina Clinical Hospital, Bucharest, Romania

Correspondence Address:
Dr. Adrian Saftoiu
66 1 Mai Bvd, Craiova 200638
Romania

Pancreatic cystic lesions (PCLs) are being increasingly encountered in clinical practice, and sometimes, they can represent a diagnostic challenge. Recently, a through-the-needle micro forceps biopsy (MFB) device was introduced in the endosonography practice to facilitate EUS-guided sampling of PCLs. The aim was to perform a systematic review of studies evaluating the technical aspects, safety, and efficacy of the EUS-guided MFB for PCLs. A literature search was performed in three major databases, PubMed, Embase, and Web of Science in September 2019 using the search terms: “through-the-needle,” “biopsy forceps,” “microforceps,” “endoscopic ultrasound,” and “endosonography.” Case reports and case series with <10 patients were excluded from the analysis. Altogether nine studies reporting on 463 patients were included in our systematic review. The mean age of the patients was 68.3 years, with a slight female predominance (60.9%). Most of the cysts were located in the body/tail of the pancreas (61.2%), with an overall mean size of 33 mm. The technical success of EUS-guided MFB was reported in 98.5%. The tissue acquisition yield reported was 88.2%, and the diagnostic accuracy was 68.6%. Adverse events were reported in 9.7%. EUS-guided MFB is technically feasible, safe, and has a high diagnostic accuracy for PCLs.


How to cite this article:
Balaban VD, Cazacu IM, Pinte L, Jinga M, Bhutani MS, Saftoiu A. EUS-through-the-needle microbiopsy forceps in pancreatic cystic lesions: A systematic review.Endosc Ultrasound 2021;10:19-24


How to cite this URL:
Balaban VD, Cazacu IM, Pinte L, Jinga M, Bhutani MS, Saftoiu A. EUS-through-the-needle microbiopsy forceps in pancreatic cystic lesions: A systematic review. Endosc Ultrasound [serial online] 2021 [cited 2021 Apr 12 ];10:19-24
Available from: http://www.eusjournal.com/article.asp?issn=2303-9027;year=2021;volume=10;issue=1;spage=19;epage=24;aulast=Balaban;type=0